Clinical Trials Browser

Phase 1/2 × pasireotide × Genitourinary × Clear all

NCT01468532 2021-03-25

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

18 enrolled 15 charts

Prostatic Neoplasms